Role of pharmacoproteomics in the development of personalized medicine

Pharmacogenomics

Volumn 5, Issue 3, 2004, Pages 331-336

  Jain, K K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Drug development; Mitochondrial proteome; Molecular diagnostics; Personalized medicine; Pharmacogenomics; Pharmacoproteomics; Protein biochips microarrays; Protein misfolding; Proteomics; Toxicoproteomics

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; DOXORUBICIN; GENTAMICIN; INSULIN; MEVINOLIN; MITOCHONDRIAL PROTEIN; PRION PROTEIN; PROTEOME;

ALZHEIMER DISEASE; ARTICLE; BIOINFORMATICS; BIOSENSOR; BIOTECHNOLOGY; BREAST CANCER; CARDIOTOXICITY; CREUTZFELDT JAKOB DISEASE; DISEASE MARKER; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MICROARRAY; PROTEOMICS;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSIS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PROTEOMICS;

EID: 9244226956     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.3.331.29830     Document Type: Article

References (18)

1. Jain KK: Proteomics: Technologies, Markets and Companies. Jain PharmaBiotech Publications, Basel, Switzerland (2004).
2. Jain KK: Personalised medicine. Curr. Opin. Mol. Ther. 4, 548-558 (2002).
3. Jain KK: Personalized Medicine: Scientific and Commercial Aspects. Jain PharmaBiotech Publications, Basel, Switzerland (2004).
4. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identily ovarian cancer. Lancet 359, 572-577 (2002).
5. Garin J, Diez R, Kieffer S et al.: The phagosome proteome. Insight into phagosome functions. J. Cell Biol. 152, 165-180 (2001).
6. Gromov PS, Ostergaard M, Gromova I, Celis JE: Human proteomic databases: a powerful resource for functional genomics in health and disease. Prog. Biophys. Mol. Biol. 80, 3-22 (2002).
7. Aguzzi A, Haass C: Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302, 814-818 (2003).
8. Morello JP, Petaja-Repo UE, Bichet DG, Bouvier M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. 21, 466-474 (2000).
9. Leanos-Miranda A, Janovick JA, Conn PM: Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 87, 4825-4828 (2002).
10. Lopez MF, Melov S: Applied proteomics: mitochondrial proteins and effect on function. Circ. Res. 90, 380-389 (2002).
11. Plasterer TN, Smith TF, Mohr SC: Survey of human mitochondrial diseases using new genomic/proteomic tools. Genome Biol. 2, research0021.1-0021.16 (2001).
12. Witzmann FA, Grant RA: Pharmacoproteomics in drug development. Pharmacogenomics J. 3, 69-76 (2003).
13. Jain KK: Applications of proteomics technologies for drug discovery. In: Biomedical and Pharmaceutical Applications of Proteomics. Hondermark H (Ed.), Kluwer Academic Publisher, the Netherlands (2004) (In Press).
14. Bandara LR, Kennedy S: Toxicoproteomics - a new preclinical tool. Drug Disc. Today 7, 411-418 (2002).
15. Waters M, Boorman G, Bushel P et al.: Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenomics 111 (1T), 15-28 (2003).
16. Man WJ, White IR, Bryant D et al.: Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2, 1577-1585 (2002).
17. Kennedy S: Proteomic profiling from human samples: the body fluid alternative. Toxicol. Lett. 120, 379-384 (2001).
18. Kang YJ: New understanding in cardiotoxicity. Curr. Opin. Drug Discov. Devel. 6, 110-116 (2003).